GlobeNewswire: Generex Biotechnology Corporation Contains the last 10 of 152 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T12:42:13ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/07/26/2268653/0/en/Generex-Biotechnology-Corporation-Subsidiary-Olaregen-Therapeutix-Announces-its-Malaysian-Distribution-Partner-Nexgen-Medical-has-gained-approval-for-the-use-of-Excellagen-Wound-Co.html?f=22&fvtc=4&fvtv=54665Generex Biotechnology Corporation Subsidiary, Olaregen Therapeutix Announces its Malaysian Distribution Partner, Nexgen Medical, has gained approval for the use of Excellagen® Wound Conforming Matrix from The Malaysian Ministry of Health, its country’s equivalent to the U.S. FDA2021-07-26T13:00:00Z<![CDATA[MIRAMAR, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) subsidiary Olaregen Therapeutix announced in May that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be Generex’s exclusive distributor to import, market and sell the Excellagen line of wound care products in Malaysia pending their Ministry of Health’s approval. We are pleased to announce that Nexgen did, in fact, receive The Malaysian Ministry of Health approval. Nexgen has committed to purchasing 1,000 units of Excellagen in year one, with an initial purchase of 500 units 0.8cc syringes of Excellagen. We plan to support our Partners roll out plan as we embark on our previously announced restart with our manufacturing which was completed, and we now await our fill finish & packaging to support our VA rollout as well as Nexgen.]]>https://www.globenewswire.com/news-release/2021/06/22/2251174/0/en/NuGenerex-Immuno-Oncology-Secures-535-Million-Valuation-from-World-Class-Independent-Valuation-Appraisal-Firm.html?f=22&fvtc=4&fvtv=54665NuGenerex Immuno-Oncology Secures $535 Million Valuation from World-Class Independent Valuation & Appraisal Firm2021-06-22T14:17:21Z<![CDATA[MIRAMAR, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO – www.nugenerexio.com), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care today announced that the company has received a $535 million valuation from an internationally recognized, independent valuation and appraisal firm that provides valuation advisory services and fairness opinions to public and private companies. NGIO received the valuation as of November 15, 2020, and since then has made significant progress in the vaccine development programs, including completion of the GMP manufacturing of the Ii-Key-SARS-CoV-2 vaccine to potentially increase this valuation. The final lot release of the COVID-19 vaccine from the manufacturer for use in clinical trials is scheduled for July. Stability studies are ongoing to support the IND, which is currently being compiled for submission to FDA. Contingent on FDA approval and the receipt of financing the final vaccine manufacturing process is commercial ready using a lyophilization method that produces a stable, powdered Ii-Key-SARS-CoV-2 vaccine that can potentially be shipped and stored at room temperature, providing a substantial commercial advantage.]]>https://www.globenewswire.com/news-release/2021/05/11/2227312/0/en/Generex-Biotechnology-Subsidiary-NuGenHealth-Contracts-with-Westside-Medicine-Cardiology-Inc-to-Provide-Remote-Patient-Monitoring-RPM-Services.html?f=22&fvtc=4&fvtv=54665Generex Biotechnology Subsidiary NuGenHealth Contracts with Westside Medicine & Cardiology, Inc. to Provide Remote Patient Monitoring (RPM) Services2021-05-11T13:00:00Z<![CDATA[MIRAMAR, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine™” to fight SARS-CoV-2, announced today that its subsidiary NuGenHealth has signed a contract with Westside Medicine & Cardiology, Inc. (WM&C) to provide connected care solutions for patient engagement and Remote Patient Monitoring (RPM) services. NuGenHealth, a joint venture between Generex subsidiary NuGenerex Health and Worldwide Digitech, LLC (WWDT) will provide the software, data framework, and back-end support for the NuGenHealth SaaS system to advance collaborative, connected care to improve patient health outcomes for patients under the care of WM&C.]]>https://www.globenewswire.com/news-release/2021/05/10/2226324/0/en/Generex-Posts-Recording-of-May-6-Shareholder-Conference-Call-Highlighting-its-Ii-Key-COVID-Complete-Vaccine-and-its-Go-Forward-Plans-for-Revenue-Producing-Assets.html?f=22&fvtc=4&fvtv=54665Generex Posts Recording of May 6 Shareholder Conference Call Highlighting its Ii-Key COVID Complete Vaccine™ and its Go-Forward Plans for Revenue Producing Assets2021-05-10T13:00:00Z<![CDATA[MIRAMAR, Fla., May 10, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine™” to fight SARS-CoV-2, today announced that the company has posted the recording from the May 6, 2021 shareholders conference call on our website at www.generex.com. The written transcript will also be posted on the website this week.]]>https://www.globenewswire.com/news-release/2021/05/06/2224553/0/en/Generex-Biotechnology-Subsidiary-NuGenHealth-Contracts-with-Florida-Health-Care-Associates-to-Provide-Remote-Patient-Monitoring-RPM-Services.html?f=22&fvtc=4&fvtv=54665Generex Biotechnology Subsidiary NuGenHealth Contracts with Florida Health Care Associates to Provide Remote Patient Monitoring (RPM) Services2021-05-06T12:30:00Z<![CDATA[MIRAMAR, Fla., May 06, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine” to fight SARS-CoV-2, announces today that its subsidiary NuGenHealth has signed a contract with Florida Health Care Associates (FHCA) to provide connected care solutions for patient engagement and Remote Patient Monitoring (RPM) services. NuGenHealth, a joint venture between Generex subsidiary NuGenerex Health and Worldwide Digitech, LLC (WWDT) will provide the software, data framework and back-end support for the NuGenHealth SaaS system to advance collaborative, connected care in order to improve patient health outcomes for patients under the care of FHCA.]]>https://www.globenewswire.com/news-release/2021/05/05/2223729/0/en/Generex-Provides-Clarification-on-Its-Ii-Key-COVID-19-Complete-Vaccine-China-Partnership-Agreement.html?f=22&fvtc=4&fvtv=54665Generex Provides Clarification on Its Ii-Key COVID-19 Complete Vaccine China Partnership Agreement2021-05-05T16:20:32Z<![CDATA[MIRAMAR, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine” to fight SARS-CoV-2, today provided guidance on the terms of its agreement with Beijing Youfeng Biological Technology, Ltd (Youfeng-BI) in connection with the $2,000,000 payment made by Youfeng-BI to GNBT and its subsidiary NuGenerex Immuno-Oncology, Inc. (NGIO) on or about April 27, 2021. Under the terms of this agreement:]]>https://www.globenewswire.com/news-release/2021/05/04/2222698/0/en/Generex-Biotechnology-Announces-Call-in-Details-and-Agenda-for-Shareholder-Conference-Call-on-Thursday-May-6-2021-at-9-00-AM.html?f=22&fvtc=4&fvtv=54665Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Thursday May 6, 2021 at 9:00 AM 2021-05-04T17:12:30Z<![CDATA[MIRAMAR, Fla., May 04, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine” to fight SARS-CoV-2, today announced the call in details and an updated agenda for the shareholder conference call on Thursday May 6, 2021 at 9:00 AM.]]>https://www.globenewswire.com/news-release/2021/05/03/2221439/0/en/Generex-Biotechnology-Subsidiary-Olaregen-Therapeutix-Announces-Agreement-with-Nexgen-Medical-for-Distribution-of-Excellagen-Wound-Conforming-Matrix-in-Malaysia.html?f=22&fvtc=4&fvtv=54665Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Agreement with Nexgen Medical for Distribution of Excellagen® Wound Conforming Matrix in Malaysia2021-05-03T13:00:00Z<![CDATA[MIRAMAR, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) subsidiary Olaregen Therapeutix today announced that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be Generex’s exclusive distributor to import, market and sell the Excellagen line of wound care products in Malaysia. Nexgen is coordinating the approval of Excellagen with the Malaysian Ministry of Health and expects commercial approval by the end of May 2021. Nexgen has committed to purchasing 1,000 units of Excellagen in year one, with an initial purchase of 500 units 0.8cc syringes of Excellagen.]]>https://www.globenewswire.com/news-release/2021/04/27/2217698/0/en/Generex-Provides-Update-on-its-Ii-Key-COVID-19-Complete-Vaccine-Program-Advancing-Global-Development.html?f=22&fvtc=4&fvtv=54665Generex Provides Update on its Ii-Key COVID-19 Complete Vaccine Program: Advancing Global Development2021-04-27T12:30:00Z<![CDATA[MIRAMAR, Fla., April 27, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that in connection with its partnership with the National Institute for Viral Disease Control and Prevention, Chinese Centre for Disease Control and Prevention, Beijing Youfeng International Consulting Co., Ltd and Beijing Guoxin Haixiang Equity Investment Partnership, the company has received a $2 million development payment from Beijing Youfeng Biological Technology, Ltd (Youfeng-BI). In exchange for this payment, Generex will provide to Youfeng-BI and our Chinese partners research results, data, regulatory documents, and manufacturing methods to support the filing of an Investigative New Drug (IND) application for the Ii-Key-SARS-CoV-2 Vaccine in China. Pursuant to the partnership, the company’s partners in China are responsible for the development and regulatory approval of the Ii-Key COVID Vaccine by the NMPA in China. All clinical trials will be conducted under guidelines of the International Council on Harmonisation (ICH), so the data can be used for submission to FDA, EMEA, and other international regulatory agencies; Generex Biotechnology Corporation and NuGenerex Immuno-Oncology maintain the rights to the Ii-Key-SARS-CoV-2 Vaccine in the rest of the world outside China.]]>https://www.globenewswire.com/news-release/2021/04/12/2208197/0/en/NuGenerex-Immuno-Oncology-Submits-Protocol-Data-and-Manufacturing-Information-to-FDA-in-Advance-of-the-IND-Submission.html?f=22&fvtc=4&fvtv=54665NuGenerex Immuno-Oncology Submits Protocol, Data, and Manufacturing Information to FDA in Advance of the IND Submission2021-04-12T12:00:00Z<![CDATA[MIRAMAR, Fla., April 12, 2021 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO – www.nugenerexio.com), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine” to fight SARS-CoV-2, today announced the company has submitted a response package to the FDA’s comments in their Pre-IND Written Response. The package provides the data and information requested by FDA, including:]]>